Endo International PLC (ENDP) Stock
ENDP is no longer traded. Endo International was delisted from the Nasdaq in October 2022.
Prices on this page are historical; the last trade was October 27, 2022 at $0.14.
Endo International stock price history
ENDP final trading statistics
- Final close
- $0.14
- Final trading day
- Oct 27, 2022
- Market cap at delisting
- $68.80M
- Shares outstanding
- 235.14M
- Final 52-week range
- $0.08 – $7.07
- Avg. volume (final 3 mo.)
- 25,885,683
- All-time high (split-adj.)
- $95.92 · Apr 2015
- All-time low (split-adj.)
- $0.09 · Oct 2022
- Return since IPO
- -98.7%
- Beta
- 1.15
- Book value / share
- -$2.61
- Price / book
- -0.05
Endo International annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $2.99B | -$569.1M | $3.02 |
| FY2020 | $2.90B | $183.9M | $2.87 |
| FY2019 | $2.91B | -$422.6M | $2.39 |
| FY2018 | $2.95B | -$1.0B | $2.89 |
| FY2017 | $3.47B | -$2.0B | $3.84 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Endo International PLC
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court
Endo International stock FAQ
What happened to Endo International stock?
Endo International stock was delisted from the Nasdaq. Its final close was $0.14 on October 27, 2022.
Is ENDP stock still trading?
No. ENDP was delisted from the Nasdaq in October 2022 and no longer trades on a U.S. exchange.
What was the last price of ENDP stock?
ENDP closed at $0.14 on its final trading day, October 27, 2022, for a market value of about $68.80M.
What were Endo International's revenue and earnings in its last full fiscal year?
Endo International reported revenue of $2.99B and net income of -$569.1M in fiscal 2021, its last full year as a public company.
When did Endo International go public?
Endo International PLC stock began trading on September 25, 1996.